Precision BioSciences, Inc.
DTIL · NASDAQ
Market closed$7.87$-0.450000 (-5.41%)After hours $7.82 · -0.59%
Key statistics
Previous close$8.32
Open$8.05
Day high$8.35
Day low$7.85
52-week high$9.62
52-week low$3.53
Market cap100.96M
Volume287.00K
Average volume412.64K
P/E ratio-1.99
Forward P/E—
EPS-3.95
Dividend yield0.00%
Market context
Why it moved
DTIL shares declined sharply today amid broad selling pressure and a lack of positive catalysts, as no company-specific news emerged to support the stock while overall market sentiment weighed on small-cap biotech names.
What is happening
Recent company-specific developments and publisher coverage.
Moomoo · July 9, 2026H.C. Wainwright Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $60Stock Titan · July 1, 2026Precision BioSciences (NASDAQ: DTIL) shares HBV data, DMD trial timelinePrecision BioSciences · May 27, 2026Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026Investing.com · May 27, 2026Precision BioSciences stock jumps on hepatitis B trial dataBioSpace · May 22, 2026Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026Stock Titan · May 21, 2026Gene editing for hepatitis B: Precision BioSciences to share new dataBusiness Wire · May 5, 2026Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business UpdateEuropean AIDS Treatment Group · April 15, 2026Hepatitis B: Updates from Aligos Therapeutics, Arbutus Biopharma Corporation and Precision BioSciences Benzinga · July 1, 2026Precision Biosciences Activates Second Clinical Site At Washington University School Of Medicine As It Begins The FUNCTION-DMD Clinical Trial Evaluating PBGENE-DMD For Duchenne Muscular Dystrophy; Initial Safety Data Targeted For End-2026 Mt Newswire · June 29, 2026Precision BioSciences Joins Russell 2000 Index Mt Newswire · June 9, 2026Oppenheimer Initiates Precision BioSciences at Outperform Benzinga · May 27, 2026Why Is Precision BioSciences Stock Gaining Wednesday? Benzinga · May 27, 2026Precision BioSciences Reports PBGENE-HBV Achieves 100% pgRNA Loss And 10-Fold cccDNA Transcript Reduction In ELIMINATE-B Study Benzinga · May 21, 2026Precision BioSciences Announces Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Benzinga · May 14, 2026Precision BioSciences Announces New Preclinical Data From PBGENE-DMD Program In Oral Presentation At ASGCT 2026 Annual Meeting Benzinga · April 29, 2026Precision Biosciences Starts Phase 1/2 FUNCTION-DMD Study Of PBGENE-DMD, In Vivo Gene Editing Treatment For Duchenne Muscular Dystrophy